Moderna and Merck report successful Phase 3 mRNA cancer vaccine trial

mRNA cancer vaccine melanoma treatment INTerpath-001 trial personalized medicine oncology immunotherapy

Moderna and Merck have announced successful Phase 3 results from the INTerpath-001 clinical trial, evaluating a personalized mRNA cancer vaccine, intismeran autogene, in combination with the immunotherapy Keytruda. The trial, which involved over 1,100 patients with surgically removed stage IIB-IV melanoma, met its primary efficacy endpoint for recurrence-free survival and its secondary target for distant metastasis-free survival.

Data indicated that the combination therapy reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 59% compared to Keytruda monotherapy. The trial reported no new safety concerns. This represents the first randomized Phase 3 validation of neoantigen-based personalized cancer vaccines.

The announcement triggered significant market movement: Moderna's stock price surged approximately 177%, adding roughly $45 billion to its market capitalization, while Merck shares rose by 12%. Analysts noted that the high cost of such treatments, estimated at approximately $475,000 per dose, is driven by the complex, individualized manufacturing process required for each patient.

Entities

Intismeran autogene · Keytruda · Merck & Co. · Moderna · Moderna Inc. · Wellington Management Group LLP

Claims

What the coverage asserts, and how many sources carry each claim.

[○ 1 SOURCE] The estimated wholesale procurement cost for intismeran is approximately $475,000 per dose.
[○ 1 SOURCE] The Phase 3 trial produced no new safety concerns. rocketnews.com
[● 3 SOURCES] The INTerpath-001 trial met its primary efficacy goal for recurrence-free survival and its secondary target for distant metastasis-free survival. rocketnews.com · www.tradingview.com
[● 3 SOURCES] The trial evaluated the personalized mRNA vaccine intismeran autogene combined with Merck’s immunotherapy Keytruda in melanoma patients. rocketnews.com · www.tradingview.com
[○ 1 SOURCE] Wellington Management Group LLP increased its Moderna holdings by 4.4% during the second quarter.
[● 4 SOURCES] Moderna and Merck reported positive results from their Phase 3 INTerpath-001 clinical trial. rocketnews.com · www.tradingview.com
[● 3 SOURCES] Moderna's stock price surged approximately 177% following the clinical trial announcement. rocketnews.com · milfordasset.com
[○ 1 SOURCE] Merck shares increased by 12% on the day of the announcement. rocketnews.com
[● 4 SOURCES] The combination therapy reduced the risk of recurrence or death by 49% compared to Keytruda monotherapy. rocketnews.com · www.gazzetta.gr · www.madata.gr